Serology
Real is (less)Diluted
Accurately measure binding kinetics in conditions closer to real life and confidently characterize the tightest binders
Traditionally, pharmacokinetic studies have relied on end point methodologies such as enzyme-linked immunosorbent assay (ELISA). Although these approaches are usually compatible with biofluids, they do not provide real-time analysis and can be extremely labor-intensive. End point assays also typically require labeled reagents, which can add additional steps to workflows and have the potential to introduce artefacts.
Drug availability for pharmacokinetics is dictated by protein binding
Pharmacokinetic (PK) studies are an essential component of the drug development life cycle. Used to characterize drug exposure, predict dosing requirements, and guide formulation design, pharmacokinetics involves comprehensive evaluation of drug absorption, distribution, metabolism, and excretion (ADME) over time.
A major challenge faced by researchers studying pharmacokinetics is that the availability of drug molecules for these experiments is dictated by the extent of drug binding to proteins in biofluids such as blood, cerebrospinal fluid (CSF), and urine. These effects may differ significantly between animal models and human subjects, or even between individuals in the same study, translating to an altered pharmacokinetic profile.
Drug binding to antibodies impacts pharmacokinetic readouts
One type of drug-protein interaction that complicates pharmacokinetic analyses is drug binding to antibodies; this can impact the robustness of pharmacokinetic data in several ways. First, the antibody profile in biofluids such as serum or plasma is highly variable between individuals, meaning that drug binding changes according to antibody abundance and binding affinity. Second, drugs may induce an immune response resulting in the production of anti-drug antibodies (ADA), which can profoundly alter the pharmacokinetics by inactivating the drug or preventing its detection in downstream analyses.
Understand serum/plasma interference
Antibody profiles differ greatly between individuals. These variations, in combination with drug binding to other proteins that are present in serum or plasma, can impact on the concentration of freely circulating drug and in consequence its pharmacological effect. Pharmacokinetic studies must therefore accurately detect, quantify and characterize changes in drug binding to antibodies and other proteins within biofluids.
-
Kinetics in biofluids.
Assess drug performance in undiluted human serum and plasma samples with our robust microfluidic technology, for reliable and reproducible kinetic profiling in conditions closer to real life
-
Tight binders welcome
Measure kinetics of high affinity binders at pM affinity (KD) values with our table, low noise and low drift GCI technology.
-
Closer to real-life conditions
Gain an accurate indication of antibody concentration and identify early immune response by detecting very low levels of antibody (80 ng/mL in serum) in biofluids with our patented no-clog microfluidic technology.
Serological studies for COVID-19 research
Analysis of molecular interactions between antibodies and SARS-CoV-2 spike protein in complex matrices like patient blood serum and plasma is of great interest to researchers studying infectious diseases like COVID-19. Matrix components like serum albumin are incompatible with label-free surface-based biosensors due to potential deleterious effects on the microfluidics and high non-specific binding. The Creoptix® WAVEsystem overcomes these limitations with innovative disposable, no-clog microfluidics and crude-sample robustness normally only possible with plate-based assays (ELISA).
-
Closer to real conditions
Take advantage of the Creoptix WAVEsystem’s no-clog microfluidics to analyze and characterize (diluted) biofluids.
-
High sensitivity
Push the limits and generate high-quality binding kinetics with our sensitive GCI technology and resolve data at very low responses.
